Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Sep 28, 2014; 20(36): 13006-13014
Published online Sep 28, 2014. doi: 10.3748/wjg.v20.i36.13006
Table 1 Performance of colon capsule endoscopy after incomplete colonoscopy
nPillCam Colon™ capsule generationSame day CCEColon preparation regimentPreparation adequacyCompletion of CCEComplementation of ICAdditional FindingsStudy design details
Spada et al[33], 20081First04 L of PEG + NaP boostersFair100%100%100%Case report
Triantafyllou et al[34], 200912First04 L of PEG + NaP boosters58%8%50%30%Retrospective
Case series
Fernández-Urién et al[35], 20111First0NRNR100%100%NoneCase report
Pioche et al[37], 2012107First01 or 2 L of PEG (MoviPrep®) + NaP boosters76%83.20%NR33.6%Prospective cohort study; results are not reported separately for the incomplete colonoscopy cases (n = 77)
Alarcón-Fernández et al[39], 201334First03 L of PEG + NaP boosters64.70%77%85.30%23.5%Prospective cohort study
Triantafyllou et al[40], 201475First33%1 L of PEG + NaP boosters or 4 L of PEG160%76%91%44%Prospective cohort study
Baltes et al[41], 201345Second0PEG (MoviPrep®) + PEG/NaP boosters70%80%87%18%Prospective cohort study (preliminary data)
Spada et al[42], 201350Second04 L of PEG83%NR98%14%Prospective cohort study (preliminary data); compares CCE-CTC
Nogales et al[43], 201396SecondNRNRNR72%93%58%Prospective cohort study
Negreanu et al[44], 20143Second04 L of PEG + PEG boostersNRNR100%100%Case series
Table 2 Performance of colon capsule endoscopy for the assessment of inflammation severity and disease extent in ulcerative colitis patients, as compared to colonoscopy
nPillCam Colon™ capsule generationStudy main end-point(s)Preparation regimenAdequacy of bowel preparationCompletion of CCECCE performance compared to colonoscopyLimitations
Sung et al[50], 2012100FirstAssessment of inflammation4 L of PEG + NaP boosters64%96%High PPV, low NPV in activity evaluationLack of documentation of disease extent, histological proof of activity not reported
Manes et al[51], 201320FirstAssessment of inflammation and disease extent3 L of PEG + NaP boosters44%90%Moderate correlation in activity and extent evaluationSmall sample size, histology not reported
Meister et al[52], 201313FirstAssessment of inflammation and disease extent2.5 L of PEG (MoviPrep®) prior CCE ingestion and as boosters90%77%CCE underestimates disease activity, poor extent estimationSmall sample size, lack of histological verification of activity, histological proof of disease activity was not obtained
Hosoe et al[53], 201329SecondAssessment of inflammation2 L of PEG< 50%69%Strong correlation for activity evaluationSmall cohort, most patients had mild disease, histological proof of disease activity was not obtained
Ye et al[54], 201325FirstAssessment of inflammation and disease extent3 L of PEG + NaP boosters80%100%Strong correlation regarding disease activity/extentSmall sample size
San Juan Acosta et al[55], 201319SecondAssessment of inflammation and disease extent4 L of PEGNR84%Strong correlation in activity/extent evaluationSmall sample size, histology not reported
Singeap et al[56], 201315SecondSecondAssessment of inflammation and disease extentNRNR93%Correlates with colonoscopy findings (activity/extent), assists in the accurate diagnosis of undetermined colitisSmall sample size, histology not reported
Kobayashi et al[57], 201349Assessment of inflammation2 L PEG or 700 mL PEG + 900-1500 mL Magnesium Citrate as boosterNR69%-85%Comparable evaluation of disease severitySmall sample size, histology not reported
Oliva et al[58], 201329SecondAssessment of inflammation and disease extentPEG + NaP boosters (volumes are not reported)62%100%High PPV (100%) and NPV (85%) regarding disease activity evaluation, high agreement in disease extentSmall sample size, histology not reported